These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 36644927)

  • 1. Diagnosis of Familial Dysbetalipoproteinemia Based on the Lipid Abnormalities Driven by APOE2/E2 Genotype.
    Bea AM; Cenarro A; Marco-Bened V; Laclaustra M; Martn C; Ibarretxe D; Pint X; Arrobas T; Vials C; Civeira F; Olmos S
    Clin Chem; 2023 Feb; 69(2):140-148. PubMed ID: 36644927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A simplified diagnosis algorithm for dysbetalipoproteinemia.
    Paquette M; Bernard S; Blank D; Paré G; Baass A
    J Clin Lipidol; 2020; 14(4):431-437. PubMed ID: 32631794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contribution of
    Bea AM; Larrea-Sebal A; Marco-Benedi V; Uribe KB; Galicia-Garcia U; Lamiquiz-Moneo I; Laclaustra M; Moreno-Franco B; Fernandez-Corredoira P; Olmos S; Civeira F; Martin C; Cenarro A
    Arterioscler Thromb Vasc Biol; 2023 Jun; 43(6):1066-1077. PubMed ID: 37051929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic factors precipitating type III hyperlipoproteinemia in hypolipidemic transgenic mice expressing human apolipoprotein E2.
    Huang Y; Rall SC; Mahley RW
    Arterioscler Thromb Vasc Biol; 1997 Nov; 17(11):2817-24. PubMed ID: 9409260
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnosis of remnant hyperlipidaemia.
    Paquette M; Bernard S; Baass A
    Curr Opin Lipidol; 2022 Aug; 33(4):227-230. PubMed ID: 35942808
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dysbetalipoproteinemia: Differentiating Multifactorial Remnant Cholesterol Disease From Genetic ApoE Deficiency.
    Paquette M; Bernard S; Paré G; Baass A
    J Clin Endocrinol Metab; 2022 Jan; 107(2):538-548. PubMed ID: 34467996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of apolipoprotein E genotype on apolipoprotein B-100 metabolism in normolipidemic and hyperlipidemic subjects.
    Ooi EM; Janus ED; Grant SJ; Sinclair LM; R Barrett PH
    J Lipid Res; 2010 Aug; 51(8):2413-21. PubMed ID: 20413671
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the Non-HDL Cholesterol to Apolipoprotein B Ratio as a Screening Test for Dysbetalipoproteinemia.
    Boot CS; Middling E; Allen J; Neely RDG
    Clin Chem; 2019 Feb; 65(2):313-320. PubMed ID: 30538126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Roles of high apolipoprotein E blood levels and HDL in development of familial dysbetalipoproteinemia in ε2ε2 subjects.
    Corsetti JP; Sparks CE; Bakker SJL; Gruppen EG; Dullaart RPF
    Clin Biochem; 2018 Feb; 52():67-72. PubMed ID: 29157655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of PCSK9 inhibition with evolocumab on lipoprotein subfractions in familial dysbetalipoproteinemia (type III hyperlipidemia).
    Waldmann E; Wu L; Busygina K; Altenhofer J; Henze K; Folwaczny A; Parhofer KG
    PLoS One; 2022; 17(3):e0265838. PubMed ID: 35320320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hyperlipidemic myeloma, a rare form of acquired dysbetalipoproteinemia, in an HIV seropositive African female.
    Seedat F; Patel M; Phillip V; Mohamed F; Marais AD; Blackhurst DM; Solomon G; Currin S; Raal FJ
    Clin Chim Acta; 2021 Sep; 520():71-75. PubMed ID: 34052205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Triglyceride-rich lipoproteins of subjects heterozygous for apolipoprotein E2(Lys146-->Gln) are inefficiently converted to cholesterol-rich lipoproteins.
    Mulder M; van der Boom H; de Knijff P; Braam C; van den Maagdenberg A; Leuven JA; Havekes LM
    Atherosclerosis; 1994 Aug; 108(2):183-92. PubMed ID: 7980718
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Applicability of Diagnostic Criteria and High Prevalence of Familial Dysbetalipoproteinemia in Russia: A Pilot Study.
    Blokhina AV; Ershova AI; Kiseleva AV; Sotnikova EA; Zharikova AA; Zaicenoka M; Vyatkin YV; Ramensky VE; Kutsenko VA; Shalnova SA; Meshkov AN; Drapkina OM
    Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37685967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dysbetalipoproteinemia in a kindred with hypobetalipoproteinemia due to mutations in the genes for ApoB (ApoB-70.5) and ApoE (ApoE2).
    Groenewegen WA; Krul ES; Averna MR; Pulai J; Schonfeld G
    Arterioscler Thromb; 1994 Nov; 14(11):1695-704. PubMed ID: 7947592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyperlipidemia in APOE2 transgenic mice is ameliorated by a truncated apoE variant lacking the C-terminal domain.
    Gerritsen G; Kypreos KE; van der Zee A; Teusink B; Zannis VI; Havekes LM; van Dijk KW
    J Lipid Res; 2003 Feb; 44(2):408-14. PubMed ID: 12576523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigating Effects of Plasma Apolipoprotein E on Ischemic Heart Disease Using Mendelian Randomization Study.
    Li MY; Kwok MK; Schooling CM
    Nutrients; 2021 Jun; 13(7):. PubMed ID: 34203181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Triglyceride Metabolism Modifies Lipoprotein(a) Plasma Concentration.
    Ramos-Cáceres M; Lamiquiz-Moneo I; Cenarro A; Calmarza P; Marco-Benedí V; Bea AM; Mateo-Gallego R; Puzo J; Ordovas JM; Civeira F; Laclaustra M
    J Clin Endocrinol Metab; 2022 Aug; 107(9):e3594-e3602. PubMed ID: 35789387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma lipoproteins in familial dysbetalipoproteinemia associated with apolipoproteins E2(Arg158-->Cys), E3-Leiden, and E2(Lys146-->Gln), and effects of treatment with simvastatin.
    Zhao SP; Smelt AH; Van den Maagdenberg AM; Van Tol A; Vroom TF; Gevers Leuven JA; Frants RR; Havekes LM; Van der Laarse A; Van 't Hooft FM
    Arterioscler Thromb; 1994 Nov; 14(11):1705-16. PubMed ID: 7947593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resequencing the APOE gene reveals that rare mutations are not significant contributory factors in the development of type III hyperlipidemia.
    Evans D; Beil FU; Aberle J
    J Clin Lipidol; 2013; 7(6):671-4. PubMed ID: 24314366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tuberous xanthomas associated with olanzapine therapy and hypertriglyceridemia in the setting of a rare apolipoprotein E mutation.
    Sinnott BP; Mazzone T
    Endocr Pract; 2006; 12(2):183-7. PubMed ID: 16690468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.